Biocomposites Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 1997-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.biocomposites.com
Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Expanded Access Program (EAP) STIMULAN VG
- Conditions
- Stage IV Pressure UlcerDiabetic Foot Osteomyelitis
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Biocomposites Ltd
- Registration Number
- NCT06808568
A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.
Phase 2
Recruiting
- Conditions
- OsteomyelitisPressure Ulcer, Stage IV
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Biocomposites Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06283979
- Locations
- 🇺🇸
NYU Langone Hospital - Long Island Clinical Research Center, Mineola, New York, United States
A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis
Phase 2
Active, not recruiting
- Conditions
- Diabetic Foot Osteomyelitis
- Interventions
- Drug: STIMULAN VGDrug: Systemic Antibiotics
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Biocomposites Ltd
- Target Recruit Count
- 61
- Registration Number
- NCT05539963
- Locations
- 🇺🇸
Titan Clinical Research, Mesa, Arizona, United States
🇺🇸Axsendo Clinical Research, Phoenix, Arizona, United States
🇺🇸Perseverance Research Center, LLC, Scottsdale, Arizona, United States
News
No news found